Concepedia

Author

Christine Flefleh

Bristol-Myers Squibb (United States)

Also Known As

C Flefleh, C. Flefleh, Christine Flefleh

13

Publications

495

Citations

10

H-Index

22

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)
CF

About

Christine Flefleh is an author at Bristol-Myers Squibb (United States) specializing in radiation oncology, cancer research, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

228

2

Pharmacology

5

5

228

3

Pathology

3

3

102

4

Cancer Cell Biology

2

2

51

5

Cell Biology

1

1

41

Christine Flefleh

×

10

Publications

482

Citations

10

H-Index

YearCitations

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Feng Luo, Zheng Yang, Amy Camuso,

Clinical Cancer Research

2006

149

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

Feng Luo, Zheng Yang, Huijing Dong,

Cancer Chemotherapy and Pharmacology

2005

85

Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels

Robert A. Wild, Krista Fager, Christine Flefleh,

Molecular Cancer Therapeutics

2006

62

Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.

Rosalyn D. Blumenthal, Chris Waskewich, David M. Goldenberg,

PubMed

2001

51

BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo

Francis Y. Lee, Louis J. Lombardo, Amy Camuso,

Cancer Research

2005

41

Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts

F. Y. Lee, Amy Camuso, Stephen Castenada,

Journal of Clinical Oncology

2006

30

Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model

Feng Luo, Zheng Yang, Huijin Dong,

Clinical Cancer Research

2005

25

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Francis Y. Lee, Mei-Li Wen, Rajeev S. Bhide,

Blood

2005

18

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

Robert A. Wild, Stephen Castaneda, Christine Flefleh,

Blood

2004

11

Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development

Kelly L. Covello, Christine Flefleh, Krista Menard,

2008

10

Page 1